{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:05:09Z","timestamp":1784275509755,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009988","name":"Huzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025GY099"],"award-info":[{"award-number":["2025GY099"]}],"id":[{"id":"10.13039\/501100009988","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06214-0","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:23:32Z","timestamp":1782491012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gouty kidney disease: a tubulointerstitial paradigm reimagined\u2014early detection, precision stratification, and targeted intervention"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8936-9114","authenticated-orcid":false,"given":"Li-Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3622-3916","authenticated-orcid":false,"given":"Li","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7700-841X","authenticated-orcid":false,"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"11","key":"6214_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649\u2013662. https:\/\/doi.org\/10.1038\/nrrheum.2015.91","journal-title":"Nat Rev Rheumatol"},{"issue":"9818","key":"6214_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","volume":"379","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang F, Wang L et al (2012) Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379(9818):815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(12)60033-6","journal-title":"Lancet"},{"issue":"9","key":"6214_CR3","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","volume":"28","author":"RJ Johnson","year":"2013","unstructured":"Johnson RJ, Nakagawa T, Jalal D et al (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28(9):2221\u20132228. https:\/\/doi.org\/10.1093\/ndt\/gft029","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"6214_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in chronic kidney disease. N Engl J Med 388(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"issue":"15","key":"6214_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"issue":"3","key":"6214_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ndt\/gft248","volume":"29","author":"SR Mulay","year":"2014","unstructured":"Mulay SR, Evan AP, Anders HJ (2014) Molecular mechanisms of crystal-related kidney inflammation and injury: implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 29(3):507\u2013514. https:\/\/doi.org\/10.1093\/ndt\/gft248","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"6214_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrneph.2017.10","volume":"13","author":"SR Mulay","year":"2017","unstructured":"Mulay SR, Anders HJ (2017) Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol 13(4):226\u2013240. https:\/\/doi.org\/10.1038\/nrneph.2017.10","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"6214_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ekir.2022.11.016","volume":"8","author":"RJ Johnson","year":"2023","unstructured":"Johnson RJ, S\u00e1nchez-Lozada LG, Lanaspa MA et al (2023) Uric acid and chronic kidney disease: still more to do. Kidney Int Rep 8(2):229\u2013239. https:\/\/doi.org\/10.1016\/j.ekir.2022.11.016","journal-title":"Kidney Int Rep"},{"issue":"1","key":"6214_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","volume":"40","author":"X Liu","year":"2018","unstructured":"Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L (2018) Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail 40(1):289\u2013297. https:\/\/doi.org\/10.1080\/0886022X.2018.1456463","journal-title":"Ren Fail"},{"issue":"7","key":"6214_CR10","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.ekir.2022.03.033","volume":"7","author":"JG Amatruda","year":"2022","unstructured":"Amatruda JG, Katz R, Sarnak MJ et al (2022) Biomarkers of kidney tubule disease and risk of end-stage kidney disease in persons with diabetes and CKD. Kidney Int Rep 7(7):1514\u20131523. https:\/\/doi.org\/10.1016\/j.ekir.2022.03.033","journal-title":"Kidney Int Rep"},{"issue":"15","key":"6214_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2011.451","volume":"305","author":"N Tangri","year":"2011","unstructured":"Tangri N, Stevens LA, Griffith J et al (2011) A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305(15):1553\u20131559. https:\/\/doi.org\/10.1001\/jama.2011.451","journal-title":"JAMA"},{"issue":"4","key":"6214_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C et al (2015) Rising burden of gout and suboptimal management in the UK: a nationwide population study. Ann Rheum Dis 74(4):661\u2013667. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204463","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6214_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11255-013-0528-6","volume":"46","author":"A Lubas","year":"2014","unstructured":"Lubas A, Kade G, Niemczyk S (2014) Renal resistive index and vascular damage in hypertension and diabetes. Int Urol Nephrol 46(2):395\u2013402. https:\/\/doi.org\/10.1007\/s11255-013-0528-6","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"6214_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2369-13-139","volume":"13","author":"N Big\u00e9","year":"2012","unstructured":"Big\u00e9 N, L\u00e9vy PP, Callard P et al (2012) Renal arterial resistive index is associated with severe histological changes and poor renal outcome during chronic kidney disease. BMC Nephrol 13(1):139. https:\/\/doi.org\/10.1186\/1471-2369-13-139","journal-title":"BMC Nephrol"},{"issue":"2","key":"6214_CR15","doi-asserted-by":"publisher","first-page":"e22259","DOI":"10.1002\/jcla.22305","volume":"32","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Ma J, Li N, Wang Y, Xu F, Liu R et al (2018) A study on the biological reference interval of urinary alpha 1-microglobulin in a group of Chinese people. J Clin Lab Anal 32(2):e22259. https:\/\/doi.org\/10.1002\/jcla.22305","journal-title":"J Clin Lab Anal"},{"issue":"24","key":"6214_CR16","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K et al (2014) Decline in eGFR and risk of ESRD and mortality. JAMA 311(24):2518\u20132531. https:\/\/doi.org\/10.1001\/jama.2014.6634","journal-title":"JAMA"},{"issue":"4 Suppl","key":"6214_CR17","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4 Suppl):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"issue":"10","key":"6214_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH et al (2016) Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 134(10):752\u2013772. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"issue":"4","key":"6214_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/ndt\/gfae203","volume":"40","author":"KJ Mayne","year":"2025","unstructured":"Mayne KJ, Sardell RJ, Staplin N et al (2025) Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant 40(4):720\u2013730. https:\/\/doi.org\/10.1093\/ndt\/gfae203","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"6214_CR20","doi-asserted-by":"publisher","first-page":"rkae094","DOI":"10.1093\/rap\/rkae094","volume":"8","author":"W Dang","year":"2024","unstructured":"Dang W, Luo H, Hu J, Liu J (2024) Analysis of risk factors for changes of renal artery resistance indexes in gout patients by ultrasound colour Doppler. Rheumatol Adv Pract 8(4):rkae094. https:\/\/doi.org\/10.1093\/rap\/rkae094","journal-title":"Rheumatol Adv Pract"},{"issue":"10","key":"6214_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240402","volume":"15","author":"T Sofue","year":"2020","unstructured":"Sofue T, Nakagawa N, Kanda E et al (2020) Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: a nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 15(10):e0240402. https:\/\/doi.org\/10.1371\/journal.pone.0240402","journal-title":"PLoS One"},{"issue":"3","key":"6214_CR22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2337\/dc25-1713","volume":"49","author":"N McCormick","year":"2026","unstructured":"McCormick N, Burrack N, Yokose C et al (2026) Gout-related medication use after initiating sodium-glucose cotransporter 2 inhibitors in patients with gout and type 2 diabetes: population-based target trial emulation studies. Diabetes Care 49(3):460\u2013470. https:\/\/doi.org\/10.2337\/dc25-1713","journal-title":"Diabetes Care"},{"key":"6214_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1667438","volume":"16","author":"EA Habeeb","year":"2025","unstructured":"Habeeb EA, Ghaith AM, Alshehri AM et al (2025) Revealing the hidden impact of SGLT2 inhibitors on uric acid levels: a retrospective multicenter cohort study. Front Endocrinol (Lausanne) 16:1667438. https:\/\/doi.org\/10.3389\/fendo.2025.1667438","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6214_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5049\/EBP.2025.23.e5","volume":"23","author":"E Bae","year":"2025","unstructured":"Bae E (2025) Mechanism of sodium-glucose cotransporter-2 inhibitors for uricosuria. Electrolyte Blood Press 23(2):23\u201330. https:\/\/doi.org\/10.5049\/EBP.2025.23.e5","journal-title":"Electrolyte Blood Press"},{"key":"6214_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1722245","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Chen Z, Zhang Y et al (2025) Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies. Front Endocrinol (Lausanne) 16:1722245. https:\/\/doi.org\/10.3389\/fendo.2025.1722245","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6214_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/medsci14010012","volume":"14","author":"R Fejes","year":"2025","unstructured":"Fejes R, J\u00e1mbor T, Lantos T, Tall\u00f3sy SP (2025) Comparison of the efficacy of empagliflozin, dapagliflozin, and allopurinol based on serum uric acid levels and kidney function in patients with type 2 diabetes mellitus: a retrospective cohort study. Med Sci (Basel) 14(1):12. https:\/\/doi.org\/10.3390\/medsci14010012","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"6214_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-025-00853-7","volume":"17","author":"T Izutsu","year":"2026","unstructured":"Izutsu T, Ito H, Matsumoto S et al (2026) Relationship between changes in uric acid levels and renal function during 12 months of treatment with luseogliflozin. Diabetol Int 17(1):7. https:\/\/doi.org\/10.1007\/s13340-025-00853-7","journal-title":"Diabetol Int"},{"issue":"30","key":"6214_CR28","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.2174\/0929867326666181211094421","volume":"27","author":"J Pan","year":"2020","unstructured":"Pan J, Shi M, Ma L, Fu P (2020) Mechanistic insights of soluble uric acid-related kidney disease. Curr Med Chem 27(30):5056\u20135066. https:\/\/doi.org\/10.2174\/0929867326666181211094421","journal-title":"Curr Med Chem"},{"issue":"6","key":"6214_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100834","volume":"6","author":"JG Amatruda","year":"2024","unstructured":"Amatruda JG, Katz R, Rebholz CM et al (2024) Urine biomarkers of kidney tubule health and risk of incident CKD in persons without diabetes: the ARIC, MESA, and REGARDS studies. Kidney Med 6(6):100834. https:\/\/doi.org\/10.1016\/j.xkme.2024.100834","journal-title":"Kidney Med"},{"issue":"3","key":"6214_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.34067\/KID.0000001015","volume":"7","author":"E Russo","year":"2026","unstructured":"Russo E, Venturelli E, Di Vincenzo J et al (2026) Dapagliflozin mitigates medullary hypoxia in CKD patients: analysis of blood oxygenation level-dependent magnetic resonance imaging renal data from the randomized Glucose Transport and Renal Protection in CKD trial. Kidney360 7(3):535\u2013546. https:\/\/doi.org\/10.34067\/KID.0000001015","journal-title":"Kidney360"},{"issue":"1","key":"6214_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.kint.2020.08.024","volume":"99","author":"T Bardin","year":"2021","unstructured":"Bardin T, Nguyen QD, Tran KM et al (2021) A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int 99(1):218\u2013226. https:\/\/doi.org\/10.1016\/j.kint.2020.08.024","journal-title":"Kidney Int"},{"issue":"1","key":"6214_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-02040-9","volume":"18","author":"BM Mahboub","year":"2025","unstructured":"Mahboub BM, Refaie AF, El-Haggar SM et al (2025) Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial. Diabetol Metab Syndr 18(1):17. https:\/\/doi.org\/10.1186\/s13098-025-02040-9","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"6214_CR33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"issue":"1","key":"6214_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","volume":"185","author":"Y Wang","year":"2025","unstructured":"Wang Y, Dalbeth N, Terkeltaub R et al (2025) Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern Med 185(1):74\u201382. https:\/\/doi.org\/10.1001\/jamainternmed.2024.6212","journal-title":"JAMA Intern Med"},{"issue":"5","key":"6214_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.ajkd.2024.04.017","volume":"84","author":"LN Helget","year":"2024","unstructured":"Helget LN, Davis-Karim A, O\u2019Dell JR et al (2024) Efficacy and safety of allopurinol and febuxostat in patients with gout and CKD: subgroup analysis of the STOP Gout trial. Am J Kidney Dis 84(5):538\u2013545. https:\/\/doi.org\/10.1053\/j.ajkd.2024.04.017","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"6214_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-007-0421-7","volume":"28","author":"F De Leonardis","year":"2007","unstructured":"De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F (2007) Elderly-onset gout: a review. Rheumatol Int 28(1):1\u20136. https:\/\/doi.org\/10.1007\/s00296-007-0421-7","journal-title":"Rheumatol Int"},{"key":"6214_CR37","doi-asserted-by":"publisher","first-page":"1830649","DOI":"10.3389\/fimmu.2026.1830649","volume":"17","author":"S Pu","year":"2026","unstructured":"Pu S, Xiao N, Li D, Cai X, Xie J (2026) Study on the pro-inflammatory injury of neutrophil extracellular traps in gouty nephropathy. Front Immunol 17:1830649. https:\/\/doi.org\/10.3389\/fimmu.2026.1830649","journal-title":"Front Immunol"},{"key":"6214_CR38","doi-asserted-by":"publisher","first-page":"1726111","DOI":"10.3389\/fmed.2025.1726111","volume":"12","author":"J Dom\u00e9nech-Serrano","year":"2025","unstructured":"Dom\u00e9nech-Serrano J, Garc\u00eda-Loiseau I, Rodr\u00edguez-Alvear C et al (2025) Combination of sodium-glucose cotransporter type 2 inhibitors and urate-lowering therapy in people with gout from a specialist clinic: a retrospective, single-center observational study. Front Med (Lausanne) 12:1726111. https:\/\/doi.org\/10.3389\/fmed.2025.1726111","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"6214_CR39","doi-asserted-by":"publisher","first-page":"2668232","DOI":"10.1080\/07853890.2026.2668232","volume":"58","author":"Q Liu","year":"2026","unstructured":"Liu Q, Hu Y, He R, Fang Z, He W (2026) A treat-to-target urate management strategy does not improve kidney outcome in patients with chronic kidney disease and asymptomatic hyperuricemia: a target trial emulation. Ann Med 58(1):2668232. https:\/\/doi.org\/10.1080\/07853890.2026.2668232","journal-title":"Ann Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06214-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06214-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:16:54Z","timestamp":1784272614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06214-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6214"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06214-0","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used DeepSeek Reasoner (accessed May - June 2026) to assist with literature search and organization, language refinement, and response to reviewer comments. All AI-generated content was substantively reviewed and edited by the authors, who take full responsibility for the integrity and accuracy of the work.","order":2,"name":"Ethics","label":"AI Use Declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that this manuscript is original, has not been published previously, and is not under consideration for publication elsewhere. No content in this review was copied from other sources. Artificial intelligence tools were used only for language polishing and structural assistance, and all scientific content, figures, and tables were prepared independently by the authors.","order":3,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"169"}}